Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss.
Anaesth Rep · 2024
Last updated 2026-08-29Two patients taking semaglutide for weight loss experienced regurgitation of stomach contents during surgery, despite following standard fasting rules. Semaglutide slows stomach emptying, which may increase the risk of this complication. Doctors suggest precautions like rapid sequence induction or using a stomach ultrasound to check for fullness before surgery.
AI summary of the abstract below.
| Journal | Anaesth Rep, 2024 |
|---|---|
| Citations | 37 |
| Relative citation ratio | 7.35 |
| NIH percentile | 96 |
| Molecules | semaglutide |
Abstract
Semaglutide is a new weight loss treatment that has received substantial media attention in recent years. Anaesthetists must be aware of a potentially dangerous side effect of the drug: decreased gastric emptying. This is caused by effects on gastric smooth muscle, mediated by the vagal afferent nerves. This is especially relevant in the peri-operative setting where pulmonary aspiration of gastric contents is a recognised complication. Here, we report two cases of peri-operative regurgitation of gastric contents in patients taking semaglutide. A patient taking semaglutide may have a full stomach despite compliance with routine pre-operative fasting guidelines. We consider how to manage patients receiving glucagon-like peptide-1 agonist therapy in the peri-operative period, including identifying those at high risk of regurgitation. Precautions such as rapid sequence induction and tracheal intubation can be used, but gastric ultrasound may also be useful in the pre-operative environment to help identify patients at high risk of aspiration.
Verbatim abstract via PubMed 38225986 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.